RSS-Feed abonnieren
DOI: 10.1055/a-1897-5992
Homocysteine and the Mortality of Critically Ill Patients: A Meta-Analysis
![](https://www.thieme-connect.de/media/hmr/202209/lookinside/thumbnails/2022-05-0131_10-1055-a-1897-5992-1.jpg)
Abstract
Prevalence of hyperhomocysteinemia (HHcy) is high in critically ill patients. However, the association between serum homocysteine level and outcomes of the critically ill patients remains unknown. We performed a meta-analysis of cohort studies to comprehensively evaluate the above association. Relevant cohort studies were identified by search of electronic databases including PubMed, Embase, Web of Science, Wanfang, and CNKI from the inception of the databases to February 5, 2022. A randomized-effect model incorporating the possible between-study heterogeneity was used to pool the results. Overall, 16 cohorts with 1663 critically ill patients who were admitted to the intensive care unit (ICU) were involved in the meta-analysis. Pooled results showed that compared to non-survivors of the critical illnesses, survivors had significantly lower serum level of Hcy at ICU admission [mean difference (MD): –3.42 μmol/l, 95% confidence interval (CI): –5.89 to 0.94, p=0.007; I2=86%]. Subgroup analysis showed that the difference of Hcy between survivors and non-survivors was significant in Asian patients (MD: –8.17 μmol/l, p<0.001), but not in non-Asians (MD: 0.30 μmol/l, p=0.62; p for subgroup difference<0.001). Moreover, meta-analysis with seven cohorts, all including Chinese patients, showed that HHcy at ICU admission was independently associated with a higher risk of all-cause mortality in critically ill patients (odds ratio: 2.99, 95% CI: 2.26 to 3.97, p<0.001; I2=69%). A higher serum level of Hcy at ICU admission may be associated with an increased risk of all-cause mortality in critically ill patients, particularly in the Chinese population.
Publikationsverlauf
Eingereicht: 05. Mai 2022
Angenommen nach Revision: 27. Juni 2022
Artikel online veröffentlicht:
07. September 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart,
Germany
-
References
- 1 Koklesova L, Mazurakova A, Samec M. et al. Homocysteine metabolism as the target for predictive medical approach, disease prevention, prognosis, and treatments tailored to the person. EPMA J 2021; 1-29
- 2 Herrmann W, Herrmann M. The controversial role of HCY and vitamin B deficiency in cardiovascular diseases. Nutrients 2022; 14: 1412
- 3 Kumar A, Palfrey HA, Pathak R. et al. The metabolism and significance of homocysteine in nutrition and health. Nutr Metab (Lond) 2017; 14: 78
- 4 Lazzerini PE, Capecchi PL, Selvi E. et al. Hyperhomocysteinemia, inflammation and autoimmunity. Autoimmun Rev 2007; 6: 503-509
- 5 Finch JM, Joseph J. Homocysteine, cardiovascular inflammation, and myocardial remodeling. Cardiovasc Hematol Disord Drug Targets 2010; 10: 241-245
- 6 Kaplan P, Tatarkova Z, Sivonova MK. et al. Homocysteine and mitochondria in cardiovascular and cerebrovascular systems. Int J Mol Sci 2020; 21: 7698
- 7 Selhub J, Jacques PF, Bostom AG. et al. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Public Health Rev 2000; 28: 117-145
- 8 Zeng Y, Li FF, Yuan SQ. et al. Prevalence of hyperhomocysteinemia in China: an updated meta-analysis. Biology (Basel) 2021; 10: 959
- 9 Paganelli F, Mottola G, Fromonot J. et al. Hyperhomocysteinemia and cardiovascular disease: is the adenosinergic system the missing link?. Int J Mol Sci 2021; 22: 1690
- 10 Holmen M, Hvas AM, Arendt JFH. Hyperhomocysteinemia and ischemic stroke: a potential dose-response association - a systematic review and meta-analysis. TH Open 2021; 5: e420-e437
- 11 Zhou F, Chen S. Hyperhomocysteinemia and risk of incident cognitive outcomes: an updated dose-response meta-analysis of prospective cohort studies. Ageing Res Rev 2019; 51: 55-66
- 12 Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 2006; 136: 1726S-1730S
- 13 Mizock BA. Homocysteine and critical illness. Crit Care Med 2000; 28: 1229-1230
- 14 Salemi G, Gueli MC, D’Amelio M. et al. Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurol Sci 2009; 30: 361-364
- 15 Yuzbasioglu MF, Ozkaya M, Cakal E. et al. Changes in plasma levels of homocysteine in patients with acute pancreatitis. JOP 2008; 9: 357-361
- 16 Esse R, Barroso M, Tavares de Almeida I. et al. The contribution of homocysteine metabolism disruption to endothelial dysfunction: state-of-the-art. Int J Mol Sci 2019; 20: 867
- 17 Schindler K, Zauner C, Buchmayer H. et al. High prevalence of hyperhomocysteinemia in critically ill patients. Crit Care Med 2000; 28: 991-995
- 18 Stoiser B, Thalhammer F, El-Menyawi I. et al. Homocysteine and laminin are not prognostic markers in patients with septic inflammatory response syndrome. Clin Diagn Lab Immunol 2000; 7: 119-121
- 19 Coelho Neto A, Azevedo RP, Santos MB. et al. Homocysteine plasma levels as a marker of clinical severity in septic patients. Rev Bras Ter Intensiva 2010; 22: 327-332
- 20 Ploder M, Kurz K, Spittler A. et al. Early increase of plasma homocysteine in sepsis patients with poor outcome. Mol Med 2010; 16: 498-504
- 21 Tsantes A, Tsangaris I, Nikolopoulos G. et al. The effect of homocysteine on the clinical outcomes of ventilated patients with severe sepsis. Minerva Anestesiol 2010; 76: 787-794
- 22 Feng HY, Li WW. Association between the level of homocysteine and in-hospital death in elderly patients with pulmonary embolism. J Chin Pract Diagn Ther 2015; 29: 491-493
- 23 Chen YQ, Xiao Y, Hu DB. et al. Effect of homocysteine and cystatin levels of the prognosis of COPD patients with respiratory failure. Chin J Coal Indus Med 2020; 23: 293-298
- 24 Niu J. Diagnostic value of serum cTnI, HCY and PCT in severity of multiple trauma patients and their relationship with prognosis. Chin J Emerg Resusc Disaster Med 2020; 15: 326-330
- 25 Chen W, Li Y, Wu YH. et al. The evaluation value of serum homocysteine level for the prognosis of patients with sepsis. Chin J Clin Med 2021; 13: 73-75
- 26 Meng W, Tian W. Associations of homocysteine, procalcitonin, and D-dimer levels with severity and prognosis of patients with multiple trauma. Clin Lab 2022; 68 DOI: 10.7754/Clin.Lab.2021.210525.
- 27 Page MJ, McKenzie JE, Bossuyt PM. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71
- 28 Page MJ, Moher D, Bossuyt PM. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 2021; 372: n160
- 29 Higgins J, Thomas J. Chandler et al. Cochrane handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration. 2021 www.training.cochrane.org/handbook
- 30 Wells GA, Shea B, O’Connell D. et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
- 31 Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. 2011 www.cochranehandbook.org
- 32 Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558
- 33 Egger M, Davey Smith G, Schneider M. et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
- 34 Rahmani A, Hatefi M, Dastjerdi MM. et al. Correlation between serum homocysteine levels and outcome of patients with severe traumatic brain injury. World Neurosurg 2016; 87: 507-515
- 35 Bernstein JE, Savla P, Dong F. et al. Inflammatory markers and severity of intracerebral hemorrhage. Cureus 2018; 10: e3529
- 36 Wexler O, Gough MS, Morgan MAM. et al. Methionine metabolites in patients with sepsis. J Intensive Care Med 2018; 33: 37-47
- 37 Li HD, Xing B. Relation among homocysteine, severity and prognosis of acute pancreatitis. Chin Med 2020; 15: 721-725
- 38 Liu M, Xing B. The effect of serum homocysteine level on septic patients with acute kidney injury. Chin J Emerg Resusc Disaster Med 2021; 16: 275-278
- 39 Zhang N, Shi F, Liang H. et al. The feasibility of using Hcy, CRP, and Cys-C to analyze AMI patients’ disease conditions and prognoses. Am J Transl Res 2021; 13: 2724-2730
- 40 Molina-Lopez J, Florea D, Quintero-Osso B. et al. Pyridoxal-5’-phosphate deficiency is associated with hyperhomocysteinemia regardless of antioxidant, thiamine, riboflavin, cobalamine, and folate status in critically ill patients. Clin Nutr 2016; 35: 706-712
- 41 Hou CT, Wu YH, Huang PN. et al. Higher plasma pyridoxal 5’-phosphate is associated with better blood glucose responses in critically ill surgical patients with inadequate vitamin B-6 status. Clin Nutr 2011; 30: 478-483
- 42 Gori AM, Sofi F, Marcucci R. et al. Association between homocysteine, vitamin B(6) concentrations and inflammation. Clin Chem Lab Med 2007; 45: 1728-1736
- 43 Perna AF, Ingrosso D, De Santo NG. Homocysteine and oxidative stress. Amino Acids 2003; 25: 409-417
- 44 Lai WK, Kan MY. Homocysteine-induced endothelial dysfunction. Ann Nutr Metab 2015; 67: 1-12
- 45 Abu-Farha M, Al-Sabah S, Hammad MM. et al. Prognostic genetic markers for thrombosis in COVID-19 patients: a focused analysis on D-dimer, homocysteine and thromboembolism. Front Pharmacol 2020; 11: 587451
- 46 Wang L, Niu H, Zhang J. Homocysteine induces mitochondrial dysfunction and oxidative stress in myocardial ischemia/reperfusion injury through stimulating ROS production and the ERK1/2 signaling pathway. Exp Ther Med 2020; 20: 938-944
- 47 Long Y, Zhen X, Zhu F. et al. Hyperhomocysteinemia exacerbates cisplatin-induced acute kidney injury. Int J Biol Sci 2017; 13: 219-231
- 48 Jacques PF, Rosenberg IH, Rogers G. et al. Serum total homocysteine concentrations in adolescent and adult Americans: results from the third national health and nutrition examination survey. Am J Clin Nutr 1999; 69: 482-489
- 49 Albert MA, Glynn RJ, Buring JE. et al. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease. Am J Cardiol 2007; 99: 1246-1251
- 50 Tu W, Yan F, Chao B. et al. Status of hyperhomocysteinemia in China: results from the China stroke high-risk population screening program, 2018. Front Med 2021; 15: 903-912
- 51 Liew SC, Gupta ED. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism: epidemiology, metabolism and the associated diseases. Eur J Med Genet 2015; 58: 1-10